Skip to main content

Table 1 Baseline characteristics of successfully and unsuccessfully treated participants

From: Treatment success and mortality among adults with tuberculosis in rural eastern Uganda: a retrospective cohort study

CharacteristicsLevelTuberculosis treatment outcomeP-value
Unsuccessful
(No. (%))
Successful
(No. (%))
All participants 187 (18.9)800 (81.1) 
DistrictSoroti104 (55.6)359 (44.9)< 0.001
Kumi49 (26.2)179 (22.4) 
Ngora26 (13.9)115 (14.4) 
Serere8 (4.3)147 (18.4) 
Level of health facilityHealth Center IV67 (35.8)341 (42.6)0.221
General Hospital40 (21.4)161 (20.1) 
Referral Hospital80 (42.8)298 (37.2) 
Location of health facilityRural45 (24.1)230 (28.7)0.232
Urban142 (75.9)570 (71.2) 
Type of health facility ownershipPublic173 (92.5)707 (88.4)0.132
Private not-for-profit14 (7.5)93 (11.6) 
Year of tuberculosis treatment201569 (36.9)298 (37.2)0.322
201645 (24.1)172 (21.5) 
201747 (25.1)176 (22.0) 
201826 (13.9)154 (19.2) 
SexFemale46 (24.6)290 (36.2)0.003
Male141 (75.4)510 (63.7) 
Age category15–3473 (39.0)387 (48.4)0.037
35–5066 (35.3)262 (32.8) 
More than 5048 (25.7)151 (18.9) 
Age (mean (SD)) 41.20 (15.70)37.89 (15.15)0.008
Type of patientNew154 (82.4)708 (88.5)0.031
Previously treated33 (17.6)92 (11.5) 
Pre-therapy MTB load1+25 (13.4)117 (14.6)0.634
2+43 (23.0)215 (26.9) 
3+64 (34.2)251 (31.4) 
Diagnosis by GeneXpert55 (29.4)217 (27.1) 
Drug regimen2RHZE/4RH105 (56.1)496 (62.0)0.172
2RHZE/6HE63 (33.7)250 (31.2) 
2RHZES/1RHZE/5RHE19 (10.2)54 (6.8) 
HIV statusNegative113 (60.4)591 (73.9)< 0.001
Positive74 (39.6)209 (26.1) 
Type of Directly Observed Therapy Short CourseHealth facility12 (6.4)33 (4.1)0.247
Community175 (93.6)767 (95.9) 
Treatment supporter availabilityNo24 (12.8)98 (12.2)0.924
Yes163 (87.2)702 (87.8) 
Living in the same sub-county as that of the health facilityYes60 (39.5)312 (45.4)0.214
No92 (60.5)375 (54.6) 
  1. Note: 1) 2RHZE/4RH: 2 months of Rifampicin (R), Isoniazid (H), Pyrazinamide (Z),Ethambutol / 4 months of RH; 2) 2RHZE/6EH: 2 months of RHZE)/ 6 months of EH; 3) 2RHZES/IRHZE/5RHE: 2 months of RHZE, Streptomycin/One month of RHZE/ 5 months of RHE; 4) MTB: Mycobacterium tuberculosis